A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants with Chronic HDV Infection (ECLIPSE 1)

开始日期2025-05-29

申办/合作机构

Vir Biotechnology, Inc.

NCT06903338

/ Recruiting临床3期

A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1)

This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.

开始日期2025-03-12

申办/合作机构

Vir Biotechnology, Inc.

NCT06216470

/ Recruiting临床2期IIT

Phase II Investigator-Initiated Study to Understand the Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection

This is a Phase II Investigator-Initiated Study to understand the vaccinal effect of HBsAg monoclonal Ab VIR-3434 in chronic hepatitis B infection.
The purpose of this study is to test VIR-3434, an experimental drug that specifically targets the HBsAg of hepatitis B virus, to clear it from the body.
This is an open label study and there is no placebo used in this study. All participants will receive the VIR-3434 for 48 weeks and then follow up in the study for 48 weeks. A total duration of approximately 104 weeks including screening period for the entire study.

开始日期2024-03-13

申办/合作机构

University Health Network

100 项与 Tobevibart 相关的临床结果

登录后查看更多信息

100 项与 Tobevibart 相关的转化医学

登录后查看更多信息

100 项与 Tobevibart 相关的专利（医药）

登录后查看更多信息

项与 Tobevibart 相关的文献（医药）

2025-06-01·JHEP Reports

Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection

Article

作者: Terrell, Ashley N ; Lempp, Florian A ; Zhou, Jiayi ; Puschnik, Andreas S ; Corti, Davide ; Rocha, Evelyn ; Kaiser, Hannah ; Purcell, Lisa A

Background & Aims:

Chronic hepatitis delta virus (HDV) infection represents the most severe form of viral hepatitis. HDV is a satellite virus of hepatitis B virus (HBV) and depends on the hepatitis B surface antigen (HBsAg) for envelopment and viral entry. Tobevibart (VIR-3434) is an investigational monoclonal antibody targeting the antigenic loop of HBsAg. Elebsiran (VIR-2218) is an investigational RNAi therapeutic targeting a highly conserved region within the HBV genome. The aim of this study was to investigate the antiviral effect of tobevibart and elebsiran on HDV infection in preclinical models.

Methods:

In vitro antiviral activity was determined in an HBV/HDV coinfection model in primary human hepatocytes (PHHs) or Huh7-NTCP cells. The in vivo efficacy of a murinized version of tobevibart alone or in combination with elebsiran was evaluated in HBV/HDV-coinfected liver-chimeric mice.

Results:

Elebsiran treatment reduced levels of secreted HBsAg and infectious HDV with picomolar potency. Tobevibart exhibited pan-genotypic neutralizing activity against all tested HDV genotypes with EC₅₀ ranging from 1.1 to 4.6 ng/ml. Combination treatment with tobevibart and elebsiran reduced infectious HDV levels in HBV/HDV-coinfected PHHs in an additive manner. In vivo, compared to vehicle, treatment with elebsiran, murinized tobevibart, or their combination significantly decreased HDV RNA serum levels by 0.7 log (p <0.0001), 1.6 log (p = 0.0034) and 2.1 log (p = 0.0002), respectively (measured at day 14 for elebsiran or day 21 for murinized tobevibart and the combination). HBsAg serum levels were reduced by 0.6 log (p <0.0001), 2.0 log (p <0.0001) and 2.8 log (p <0.0001), respectively.

Conclusions:

Tobevibart and elebsiran exert potent antiviral activity as single agents and in combination. The data support the clinical development of tobevibart and elebsiran for the treatment of patients with chronic HDV infection.

Impact and implications:

Chronic hepatitis delta is the most severe form of viral hepatitis and is associated with rapid progression of liver-related diseases and a high risk of hepatocellular carcinoma development. To date, there are only limited treatment options available. Tobevibart and elebsiran are currently being evaluated in clinical trials for the treatment of HDV (phase III) and for the treatment of HBV (phase II). The current study demonstrates that tobevibart and elebsiran are efficacious in preclinical models of HBV/HDV coinfection, supporting their clinical development.

2023-11-01·Journal of hepatology

Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice.

Article

作者: Snell, Gyorgy ; Urban, Stephan ; Soriaga, Leah B ; Telenti, Amalio ; Vincenzetti, Lucia ; Zhou, Jiayi ; Noack, Julia ; Zatta, Fabrizia ; Volz, Tassilo ; Jaconi, Stefano ; Bianchi, Siro ; Purcell, Lisa A ; Kaiser, Hannah ; Cameroni, Elisabetta ; Schulze, Andreas ; Lombardo, Gloria ; Benigni, Fabio ; Corti, Davide ; Rosen, Laura E ; Belnap, David M ; Cathcart, Andrea L ; Lempp, Florian A ; Hebner, Christy M ; Imam, Hasan ; Schmid, Michael A ; Dandri, Maura ; Lütgehetmann, Marc ; Passini, Nadia

BACKGROUND & AIMS:

Chronic hepatitis B is a global public health problem, and coinfection with hepatitis delta virus (HDV) worsens disease outcome. Here, we describe a hepatitis B virus (HBV) surface antigen (HBsAg)-targeting monoclonal antibody (mAb) with the potential to treat chronic hepatitis B and chronic hepatitis D.

METHODS:

HBsAg-specific mAbs were isolated from memory B cells of HBV vaccinated individuals. In vitro neutralization was determined against HBV and HDV enveloped with HBsAg representing eight HBV genotypes. Human liver-chimeric mice were treated twice weekly with a candidate mAb starting 3 weeks post HBV inoculation (spreading phase) or during stable HBV or HBV/HDV coinfection (chronic phase).

RESULTS:

From a panel of human anti-HBs mAbs, VIR-3434 was selected and engineered for pre-clinical development. VIR-3434 targets a conserved, conformational epitope within the antigenic loop of HBsAg and neutralized HBV and HDV infection with higher potency than hepatitis B immunoglobulins in vitro. Neutralization was pan-genotypic against strains representative of HBV genotypes A-H. In the spreading phase of HBV infection in human liver-chimeric mice, a parental mAb of VIR-3434 (HBC34) prevented HBV dissemination and the increase in intrahepatic HBV RNA and covalently closed circular DNA. In the chronic phase of HBV infection or co-infection with HDV, HBC34 treatment decreased circulating HBsAg by >1 log and HDV RNA by >2 logs.

CONCLUSIONS:

The potently neutralizing anti-HBs mAb VIR-3434 reduces circulating HBsAg and HBV/HDV viremia in human liver-chimeric mice. VIR-3434 is currently in clinical development for treatment of patients with chronic hepatitis B or D.

IMPACT AND IMPLICATIONS:

Chronic infection with hepatitis B virus and co-infection with hepatitis D virus place approximately 290 million individuals worldwide at risk of severe liver disease and cancer. Available treatments result in low rates of functional cure or require lifelong therapy that does not eliminate the risk of liver disease. We isolated and characterized a potent human antibody that neutralizes hepatitis B and D viruses and reduces infection in a mouse model. This antibody could provide a new treatment for patients with chronic hepatitis B and D.

World journal of virology

Advances in treatment of hepatitis delta virus infection: Update on novel investigational drugs

Review

作者: Nasir, Syed Alishan ; Park, Jiyoon ; Sayed, Amr ; Lim, Joseph K

Chronic hepatitis delta virus (HDV) represents a rare but important co-infection in approximately 5% of patients with chronic hepatitis B virus (HBV) infection, and is associated with significant morbidity and mortality due to an increased risk for liver cirrhosis, liver failure, and hepatocellular carcinoma relative to HBV monoinfected individuals. The current treatment of chronic HDV infection includes the off-label use of pegylated interferon (IFN), which is limited by poor safety, tolerability, and efficacy. Guidelines of the major international liver organizations such as the American Association for the Study of Liver Diseases, European Association for the Study of the Liver, and Asian Pacific Association for the Study of the Liver provide recommendations for contemporary diagnosis and management of chronic HDV infection, including the incorporation of bulevirtide, a newly licensed antiviral agent in Europe. Significant unmet medical needs remain in the treatment of HDV, and recent advances in drug development offer hope for meaningful advances in drug therapy which may improve virologic response rates and clinical outcomes. This review summarizes trial design and available efficacy data from key phase 2 and 3 trials for investigational therapies including entry inhibitors (bulevirtide), prenylation inhibitors (lonafarnib), novel IFNs (peginterferon lambda), RNA interference molecules (JNJ-3989, elebsiran), monoclonal antibodies (tobevibart), and nucleic acid polymers (REP2139), and addresses future directions in HDV pharmacotherapy.

149

项与 Tobevibart 相关的新闻（医药）

2025-06-17

·PRNewswire

Chronic Hepatitis B Market--The US to Have the Lion's Share Among the 7MM, Predicts DelveInsight

The chronic hepatitis B market size is predicted to surge owing to the increasing prevalence of the disease globally and rising awareness about early diagnosis and treatment. Advances in antiviral therapies and the development of novel treatment options are fueling market expansion. LAS VEGAS, June 17, 2025 /PRNewswire/ -- Hepatitis B is the most widespread serious liver infection globally, caused by the hepatitis B virus (HBV), which targets and damages the liver. Millions of individuals worldwide are affected by chronic hepatitis B. The virus spreads through contact with infected blood and bodily fluids, including transmission via unprotected sex, sharing of contaminated needles, use of illegal drugs, and exposure to unsterilized medical equipment. In most cases, hepatitis B resolves on its own within 1 to 2 months. However, if the infection persists beyond six months, it can become chronic, potentially leading to ongoing liver inflammation, cirrhosis (liver scarring), liver cancer, or liver failure. As of 2024, around 5 million people across the 7MM were living with chronic hepatitis B. Among these, 85% had compensated liver function, while the remaining 15% had progressed to decompensated liver disease. Currently, there is no definitive cure for hepatitis B. Antiviral medications and interferon injections can help manage the disease by reducing viral activity and easing symptoms, but they do not eliminate the virus entirely. If the infection persists beyond six months, it is classified as chronic, making patients eligible for drug therapy, particularly those with active liver disease. Learn more about the chronic hepatitis B virus market @ New Treatment for Chronic Hepatitis B The US FDA has approved seven medications for treatment: two injectable interferons and five oral antiviral drugs. These treatments must be taken daily and work by suppressing viral replication, thereby reducing liver inflammation and potential damage. VEMLIDY (tenofovir alafenamide), developed by Gilead Sciences, is an innovative, targeted prodrug of tenofovir formulated as an oral tablet. In March 2024, Gilead announced that the FDA had approved a supplemental New Drug Application (sNDA) for VEMLIDY 25 mg, allowing its once-daily use in pediatric patients aged 6 years and older and weighing at least 25 kg who have chronic hepatitis B (CHB) infection with compensated liver disease. Earlier, in November 2022, the FDA approved the same 25 mg dose for once-daily use in children aged 12 and above with CHB and compensated liver disease. The initial FDA approval came in November 2016 for adult patients with CHB and compensated liver function. In January 2017, Gilead announced that the European Commission (EC) had granted marketing authorization for VEMLIDY 25 mg to treat CHB in adults and adolescents aged 12 and older who weigh at least 35 kg. Additionally, in December 2016, Japan's Ministry of Health, Labour and Welfare (MHLW) approved VEMLIDY for the treatment of chronic hepatitis B in patients showing active viral replication and abnormal liver function. Find out more on FDA-approved chronic hepatitis B drugs @ Chronic Hepatitis B (CHB) Market The chronic hepatitis B treatment drug market is continuously evolving. Several pharma companies are evaluating their lead assets in different phases of development. Many potential therapies are being investigated to manage chronic hepatitis B. Some of the drugs in the pipeline include Imdusiran (AB-729) (Arbutus Biopharma), GSK3228836 (bepirovirsen) (GlaxoSmithKline), Tobevibart (VIR-3434) + elebsiran (VIR-2218) ± PEG-IFN-a (Vir Biotechnology), and others. Even though it is too soon to comment on the above-mentioned promising candidate to enter the market during the forecast period (2025–2034), it is safe to assume that the future of this market is bright. Discover which therapies are expected to grab major chronic hepatitis B treatment drug market @ Chronic Hepatitis B Market Report Daplusiran (also known as tomligisiran, formerly JNJ-3989/GSK5637608) is an experimental siRNA-based therapy targeting hepatitis B virus (HBV). It is being studied in combination with bepirovirsen in a sequential regimen for adult patients with chronic hepatitis B who are non-cirrhotic and receiving nucleos(t)ide analogue (NA) therapy. In October 2023, GSK and Arrowhead Pharmaceuticals announced an agreement with Janssen Pharmaceuticals to acquire the exclusive global rights to further develop and commercialize JNJ-3989. Janssen had originally licensed the drug (then called ARO-HBV) from Arrowhead in 2018. Imdusiran is an RNA interference (RNAi) therapy designed to suppress all HBV viral proteins and antigens, including HBsAg, which is believed to be critical for restoring the immune system's ability to fight the virus. It uses Arbutus' proprietary GalNAc-conjugated delivery platform to specifically target liver cells (hepatocytes), allowing for subcutaneous administration. Arbutus plans to launch a Phase IIb clinical trial in the first half of 2025 to evaluate imdusiran in combination with interferon (IFN) and NA therapy. Discover more about drugs for chronic hepatitis B in development @ Chronic Hepatitis B Clinical Trials The anticipated launch of these emerging therapies for chronic hepatitis B are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the chronic hepatitis B market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for chronic hepatitis B is expected to grow at a significant CAGR by 2034. In 2024, the United States dominated the CHB market among the 7MM, capturing approximately 72% of the total market share. The market size of chronic hepatitis B is expected to grow due to several factors, including rising global prevalence of hepatitis B virus infection and increasing awareness about the disease. Advances in antiviral therapies and growing screening initiatives also boost market growth by enabling early diagnosis and improved disease management. DelveInsight's latest published market report, titled as Chronic Hepatitis B Market Insight, Epidemiology, and Market Forecast – 2034 , will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the chronic hepatitis B country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The chronic hepatitis B market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Chronic Hepatitis B Total Diagnosed Cases of Chronic Hepatitis B Chronic Hepatitis B Cases by Age Group Chronic Hepatitis B Cases by Gender Treated Cases of Chronic Hepatitis B Chronic Hepatitis B Cases by Impact on Liver The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM chronic hepatitis B market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this chronic hepatitis B market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the chronic hepatitis B market. Also, stay abreast of the mitigating factors to improve your market position in the chronic hepatitis B therapeutic space. Related Reports Chronic Hepatitis B Epidemiology Chronic Hepatitis B Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the CHB epidemiology trends. Chronic Hepatitis B Pipeline Chronic Hepatitis B Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CHB companies, including Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, among others. Hepatitis A Market Hepatitis A Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hepatitis A companies, including Boryung Pharmaceutical, Cadila Healthcare, Indian Immunologicals, Biological E Limited, among others. Hepatitis C Market Hepatitis C Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hepatitis C companies, including AbbVie, Gilead Sciences, Atea Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准引进/卖出临床2期

2025-05-26

·腾盛博药

腾盛博药7周年：创新驱动未来，坚守健康使命

自2018年成立以来，腾盛博药始终秉承“以突破性的科学创新和对患者关键需求的洞察应对公共卫生挑战”的使命，凭借领先的研发能力和突破创新，取得了一系列具有里程碑意义的进展。3个乙肝功能性治愈候选药物BRII-179、BRII-835和BRII-877均获得国家药监局的突破性治疗认定，实现又一项前所未有的科学转化成果。在全球开展了19项1期和2期临床试验在全球获得20多个创新类奖项，创新成果获得国际社会的广泛认可在全球拥有80多项专利和专利申请，推动医药创新从多个临床试验的成功推进，到多项技术和专利的积累，七年里，我们经历过市场的风云变幻，面对过研发的艰难挑战，但始终以坚定的信念在创新的道路上破浪前行。在充满挑战的医药研发过程中，我们坚持“以患者为中心”的研发理念，将科学创新转化为临床价值。未来，腾盛博药将继续深化行业合作，我们期待与志同道合的伙伴携手并进，开发更具创新性、更高效的疗法，推动公共卫生事业的发展。我们将秉持初心研发创新疗法，持续为改善公共卫生，造福全球患者贡献力量。关于腾盛博药腾盛博药（股票代码：2137.HK）是一家生物技术公司，致力于针对存在巨大未被满足的患者需求、治疗手段有限，以及给患者带来严重社会歧视的重大公共卫生挑战开发创新疗法。公司专注于感染性疾病，正在推进一条涵盖多种独特候选药物的产品管线，重点包括针对乙型肝炎病毒（HBV）感染的领先项目。在富有远见卓识和经验丰富的领导团队带领下，公司在位于罗利-达勒姆、旧金山湾区、北京和上海的主要生物技术中心开展业务。欲了解更多信息，请点击阅读原文。

突破性疗法临床2期临床1期

2025-05-12

·EndPoints

Vir’s hep B disappointment, Ipsen's new Iqirvo data, plus more from #EASL25

The annual meeting of the European Association for the Study of the Liver (EASL) has wrapped up in Amsterdam. This was perhaps not a vintage year, since many of the most important liver drugs — particularly for MASH — are in long-running Phase 3 trials and only posted incremental updates from earlier studies. Still, companies including Madrigal Pharmaceuticals and Akero Therapeutics shared intriguing data, and Ipsen and Mirum Pharmaceuticals gave updates in rarer conditions, along with Vir Biotechnology and Virion Therapeutics in hepatitis B. First up, Vir said on Friday that two out of 51 chronic hepatitis B patients — just 4% — treated with its doublet antiviral therapy had experienced a functional cure. The rate increased to 10% among a further 32 patients given the two drugs, called tobevibart and elebsiran, as well as pegylated interferon α. These rates are far below the benchmarks of around 20% and 30% for doublet and triplet, respectively, that Vir had projected, Leerink analysts wrote in a May 9 note. The data came from an ongoing Phase 2 trial called MARCH. This trial has several experimental cohorts but no control group. Functional cure in hep B is defined as undetectable levels of a viral protein called HBsAg, as well as undetectable viral DNA, in patients’ blood six months after treatment finishes and patients have come off a type of enzyme therapy used to treat the infection. The MARCH study’s primary endpoint was slightly different than functional cure, consisting of undetectable levels of the viral protein, but without the viral DNA requirement. In the doublet, 8% of recipients hit the endpoint, and in those who also received the interferon, the figure was 16%. Vir highlighted slightly better data in a subgroup who had low levels of HBsAg at baseline. Here, the functional cure rates were 11% and 15% for the doublet and triplet therapies, respectively. The rates for the primary endpoint of HBsAg seroclearance were 17% for the doublet and 21% with the triplet. Development of tobevibart and elebsiran is already in limbo. Vir said in February that it was seeking a partner for the drugs outside China, and would not start late-stage trials on its own. Such a partnership now looks less likely to emerge. However, Vir is developing the doublet for chronic hepatitis delta, where it showed promise in a Phase 2 trial called SOLSTICE last year . It has cash to last it until 2027. Ipsen also presented more data at the confab for its rare disease drug Iqirvo. It is approved for primary biliary cholangitis (PBC), but Ipsen is trying to move it into another rare liver condition — primary sclerosing cholangitis (PSC). Ipsen shared that in a mid-stage trial, 80 mg and 120 mg doses of the PPARα/δ agonist caused levels of alkaline phosphatase (ALP), a biomarker of disease progression, to drop to normal levels in 9.1% and 17.4% of patients, respectively, versus none on placebo. Reductions were also seen with the liver biomarkers alanine aminotransferase and gamma-glutamyl transferase. Analysts from RBC called the data strong, and said they address a broader patient pool than another Phase 2-stage PSC drug, Mirum’s volixibat. The company also said a new analysis of data from the ELATIVE trial, which led to the approval of Iqirvo for PBC last year , showed 42.9% of patients given the drug had improvements in fatigue as measured by the PROMIS Fatigue Short Form 7a questionnaire, versus 31.3% on placebo. Using a different measure, called the PBC-40 fatigue domain score, 22.6% of Iqirvo patients had less tiredness, versus 15.4% given placebo. Ipsen emphasized that the effect of the drug on fatigue occurs independently of its effect on the itching that is characteristic of PBC. Ipsen licensed most worldwide rights to Iqirvo from Genfit in 2021.

临床2期临床结果临床3期

100 项与 Tobevibart 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性丁型肝炎	临床3期	-	Vir Biotechnology, Inc.	2025-03-13
丁型肝炎	临床3期	美国	Vir Biotechnology, Inc.	2025-03-12
丁型肝炎	临床3期	加拿大	Vir Biotechnology, Inc.	2025-03-12
丁型肝炎	临床3期	摩尔多瓦	Vir Biotechnology, Inc.	2025-03-12
丁型肝炎	临床3期	新西兰	Vir Biotechnology, Inc.	2025-03-12
丁型肝炎	临床3期	罗马尼亚	Vir Biotechnology, Inc.	2025-03-12
丁型肝炎	临床3期	乌克兰	Vir Biotechnology, Inc.	2025-03-12
丁型肝炎	临床3期	英国	Vir Biotechnology, Inc.	2025-03-12
慢性乙型肝炎	临床2期	美国	Vir Biotechnology, Inc.	2021-07-11
慢性乙型肝炎	临床2期	加拿大	Vir Biotechnology, Inc.	2021-07-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04856085 (MARCH, Company_Website) 人工标引	临床2期	慢性乙型肝炎	83	Tobevibart + Elebsiran	積窪淵鹽壓觸遞衊艱醖(壓齋蓋廠築衊遞鬱夢鏇) = 獵簾膚糧鹽夢願鑰膚遞窪廠構鹹衊淵製餘獵簾 (襯蓋襯醖醖鬱壓網鬱製 ) 更多	积极	2025-05-09
				Tobevibart + Elebsiran + PEG-IFNα	積窪淵鹽壓觸遞衊艱醖(壓齋蓋廠築衊遞鬱夢鏇) = 餘襯積鹹顧繭衊觸蓋膚窪廠構鹹衊淵製餘獵簾 (襯蓋襯醖醖鬱壓網鬱製 ) 更多
NCT05461170 (SOLSTICE, EASL2024) 人工标引	临床2期	慢性丁型肝炎	33	Tobevibart 300 mg plus Elebsiran 200 mg	夢選鏇齋鑰鏇衊廠網鏇(鹹構艱襯鹽繭襯選餘餘) = 鏇鑰鹹範鬱淵窪遞齋鹹衊襯淵鏇獵願獵壓淵簾 (製構鏇鑰築憲選築餘襯 ) 更多	积极	2024-06-01
				Tobevibart 300 mg	夢選鏇齋鑰鏇衊廠網鏇(鹹構艱襯鹽繭襯選餘餘) = 簾鑰鹽鬱選顧獵衊製範衊襯淵鏇獵願獵壓淵簾 (製構鏇鑰築憲選築餘襯 ) 更多
NCT04856085 (MARCH, Biospace) 人工标引	临床2期	慢性乙型肝炎	-	VIR-343+VIR-2218+peginterferon alpha	鹹鑰蓋艱餘憲顧夢醖憲(廠蓋膚繭選廠鹹淵築簾) = 衊壓鹽壓觸遞淵網遞簾餘構鑰觸網蓋蓋鬱簾鑰 (顧夢糧鹹憲範構衊淵觸 ) 更多	积极	2023-11-13
				VIR-343+VIR-2218	鹹鑰蓋艱餘憲顧夢醖憲(廠蓋膚繭選廠鹹淵築簾) = 繭膚簾壓範齋鑰淵鏇積餘構鑰觸網蓋蓋鬱簾鑰 (顧夢糧鹹憲範構衊淵觸 )
EASL2022	临床1期	乙型肝炎 HBsAg \| HBeAg	-	VIR-3434 6 mg	壓膚製醖衊衊餘選製鏇(繭積鑰蓋顧簾艱範餘繭) = Ten adverse events were reported, and all were grade 1 or 2 in severity. No clinically significant laboratory abnormalities or signs of immune complex disease were observed. 顧鹹製積鑰築範顧簾製 (餘獵蓋齋鏇憲憲網憲憲 )	积极	2022-06-25
				VIR-3434 18 mg
EASL2021	临床1期	慢性乙型肝炎	8	VIR-3434 6 mg	窪壓範襯簾廠齋選廠壓(壓選獵淵夢積餘遞膚憲) = 繭築築蓋壓鑰窪衊憲積選選範築製鹹觸範積鏇 (獵鹹築糧顧衊襯構膚齋 )	-	2021-06-23
NCT04423393 (GlobeNewswire) 人工标引	临床1期	慢性乙型肝炎	8	VIR-3434	糧遞構選艱淵選積顧鬱(網齋膚願簾醖獵選積夢) = 壓餘鑰觸構壓醖襯膚網廠廠鏇積夢壓憲蓋鏇醖 (鏇遞選願鹽鑰鏇遞積襯 )	积极	2021-01-26
				Placebo	-